thalidomide has been researched along with Acute Lymphoid Leukemia in 13 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lenalidomide is often used in the maintenance setting for multiple myeloma and has been linked to the development of secondary primary malignancies." | 3.85 | Lenalidomide and secondary acute lymphoblastic leukemia: a case series. ( Fong, R; Lo, M; Tan, M; Young, R, 2017) |
| " Here, we report the success of thalidomide treatment for 2 subtypes of histiocytic proliferation--metastatic histiocytic sarcoma and extracutaneous juvenile xanthogranuloma--in pediatric patients." | 3.78 | Thalidomide therapy for aggressive histiocytic lesions in the pediatric population. ( Bailey, KM; Castle, VP; Hummel, JM; McAllister-Lucas, LM; Moyer, J; Piert, M, 2012) |
| "Lenalidomide was given orally at escalating doses of 25 to 75 mg daily on days 1 through 21 of 28-day cycles to determine the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD), as well as to provide pharmacokinetic and preliminary efficacy data." | 2.75 | Dose escalation of lenalidomide in relapsed or refractory acute leukemias. ( Becker, H; Blum, W; Byrd, JC; Chandler, JC; Curfman, J; Devine, SM; Garzon, R; Grever, MR; Kefauver, C; Klisovic, RB; Liu, S; Marcucci, G; Mickle, J; Phelps, MA; Rozewski, DM; Schaaf, L; Walker, A; Whitman, SP; Yang, X, 2010) |
| "Acute lymphoblastic leukemia (ALL) is a hematological disorder involving at least 20% lymphoblasts in the bone marrow of the B-cell lineage." | 1.39 | Acute myelofibrosis and acute lymphoblastic leukemia in an elderly patient with previously treated multiple myeloma. ( Chen, L; Gonzalez, MM; Kidd, L; Nguyen, N; Quesada, J, 2013) |
| "Thalidomide is a drug with anti-angiogenic, anti-inflammatory, immunomodulatory and anti-cancer properties that were found to inhibit the production of TNF-alpha in vitro, stimulate reactive oxygen species production, and inhibit VEGFR in acute leukemias." | 1.33 | Ex vivo activity of thalidomide in childhood acute leukemia. ( Czyzewski, K; Styczynski, J; Wysocki, M, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| García-Muñoz, R | 1 |
| Robles-de-Castro, D | 1 |
| Muñoz-Rodríguez, A | 1 |
| Rabasa, P | 1 |
| Gonzalez, MM | 1 |
| Kidd, L | 1 |
| Quesada, J | 1 |
| Nguyen, N | 1 |
| Chen, L | 1 |
| Nair, R | 1 |
| Gheith, S | 1 |
| Popescu, D | 1 |
| Agostino, NM | 1 |
| Tan, M | 1 |
| Fong, R | 1 |
| Lo, M | 1 |
| Young, R | 1 |
| Tavernier-Tardy, E | 1 |
| Cornillon, J | 1 |
| Molucon-Chabrot, C | 1 |
| Cahn, JY | 1 |
| Tinquaut, F | 1 |
| Bourmaud, A | 1 |
| Guyotat, D | 1 |
| Thomas, X | 1 |
| Stefan, DC | 1 |
| Andronikou, S | 1 |
| Freeman, N | 1 |
| Schoeman, J | 1 |
| Blum, W | 1 |
| Klisovic, RB | 1 |
| Becker, H | 1 |
| Yang, X | 1 |
| Rozewski, DM | 1 |
| Phelps, MA | 1 |
| Garzon, R | 1 |
| Walker, A | 1 |
| Chandler, JC | 1 |
| Whitman, SP | 1 |
| Curfman, J | 1 |
| Liu, S | 1 |
| Schaaf, L | 1 |
| Mickle, J | 1 |
| Kefauver, C | 1 |
| Devine, SM | 1 |
| Grever, MR | 1 |
| Marcucci, G | 1 |
| Byrd, JC | 1 |
| Chan, TS | 1 |
| Au, WY | 1 |
| Lam, K | 1 |
| Lam, YF | 1 |
| So, CC | 1 |
| Leung, AY | 1 |
| Tse, E | 1 |
| Lie, AK | 1 |
| Kwong, YL | 1 |
| Bailey, KM | 1 |
| Castle, VP | 1 |
| Hummel, JM | 1 |
| Piert, M | 1 |
| Moyer, J | 1 |
| McAllister-Lucas, LM | 1 |
| Ribatti, D | 1 |
| Scavelli, C | 1 |
| Roccaro, AM | 1 |
| Crivellato, E | 1 |
| Nico, B | 1 |
| Vacca, A | 1 |
| Styczynski, J | 1 |
| Czyzewski, K | 1 |
| Wysocki, M | 1 |
| Shalapour, S | 1 |
| Zelmer, A | 1 |
| Pfau, M | 1 |
| Moderegger, E | 1 |
| Costa-Blechschmidt, C | 1 |
| van Landeghem, FK | 1 |
| Taube, T | 1 |
| Fichtner, I | 1 |
| Bührer, C | 1 |
| Henze, G | 1 |
| Seeger, K | 1 |
| Wellmann, S | 1 |
| Lopez, J | 1 |
| Ulibarrena, C | 1 |
| Garcia-Laraña, J | 1 |
| Odriozola, J | 1 |
| Pérez de Oteyza, J | 1 |
| Sastre, JL | 1 |
| Navarro, JL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study of Pomalidomide in Anal Cancer Precursors (SPACE): a Phase 2 Study of Immunomodulation in People With Persistent HPV-associated High Grade Squamous Intraepithelial Lesions[NCT03113942] | Phase 2 | 26 participants (Actual) | Interventional | 2017-06-14 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for thalidomide and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
Acute lymphoblastic leukemia developing during maintenance therapy with lenalidomide in a patient with multiple myeloma.
Topics: Antineoplastic Agents; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; | 2013 |
Hematopoietic cancer and angiogenesis.
Topics: Angiogenesis Inhibitors; Cell Proliferation; Disease Progression; Endothelium, Vascular; Hematologic | 2004 |
2 trials available for thalidomide and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
A phase 1/2 trial of lenalidomide and dexamethasone in adult patients with refractory/relapsed acute lymphoblastic leukemia.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy | 2017 |
Dose escalation of lenalidomide in relapsed or refractory acute leukemias.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplas | 2010 |
9 other studies available for thalidomide and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
Acute myelofibrosis and acute lymphoblastic leukemia in an elderly patient with previously treated multiple myeloma.
Topics: Aged; Blood Cell Count; Bone Marrow; Humans; Immunohistochemistry; Lenalidomide; Maintenance Chemoth | 2013 |
A rare case of acute lymphoblastic leukemia in a patient with light chain (AL) amyloidosis treated with lenalidomide.
Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopsy; Birefringence | 2014 |
Lenalidomide and secondary acute lymphoblastic leukemia: a case series.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Humans; Immunologic Factors; Lenalidomide; Male; Middle | 2017 |
Recovery of vision after adjuvant thalidomide in a child with tuberculous meningitis and acute lymphoblastic leukemia.
Topics: Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Blindness; Brain; Chemother | 2009 |
Donor cell leukaemia after allogeneic haematopoietic SCT followed by prolonged thalidomide maintenance for multiple myeloma.
Topics: Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Living Donors; Ma | 2012 |
Thalidomide therapy for aggressive histiocytic lesions in the pediatric population.
Topics: Adolescent; Child; Female; Histiocytic Sarcoma; Humans; Immunosuppressive Agents; Michigan; Precurso | 2012 |
Ex vivo activity of thalidomide in childhood acute leukemia.
Topics: Angiogenesis Inhibitors; Cell Cycle; Child; Child, Preschool; Cytarabine; Female; Humans; Immunophen | 2006 |
The thalidomide analogue, CC-4047, induces apoptosis signaling and growth arrest in childhood acute lymphoblastic leukemia cells in vitro and in vivo.
Topics: Animals; Apoptosis; Blood Vessels; Caspase 3; Cell Proliferation; Child, Preschool; Female; Humans; | 2006 |
Thalidomide as therapy for intestinal chronic GVHD.
Topics: Adult; Bone Marrow Transplantation; Graft vs Host Disease; Humans; Intestinal Diseases; Male; Precur | 1993 |